Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
about
A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenStructure determination of an anti-HIV-1 Fab 447-52D–peptide complex from an epitaxially twinned data setHuman Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic StructureFunctional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsFunctional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIVPre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradicationIndirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjectsHuman monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia.Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotypingA global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection.Molecular evolution of HIV-1 CRF01_AE Env in Thai patientsHuman monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.Phages and HIV-1: from display to interplay.Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles.Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins.Interaction of the HIV-1 gp120 viral protein V3 loop with bacterial lipopolysaccharide: a pattern recognition inhibition.Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?Clonal patterns in the human immune response to HIV-1 infection.A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolateEnvelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptorFunctional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFLThe auto-regulation model: a unified concept of how HIV regulates its infectivity, pathogenesis and persistence.Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
P2860
Q27302081-E9313DEA-5DB1-4107-BA35-F7E03898B7C9Q27650903-07174F2B-4581-4A62-B7BF-66BA6287289FQ27676155-542494E9-B900-4D1D-99F3-BAC3BCC3DF44Q27677941-D913C3C4-C465-4A96-BF03-2D8846199478Q27681527-D8EB38C9-D76F-4C56-8232-711A13F9FFE7Q28731318-BF8AFB1A-2415-4B08-BCE5-67DB2F07C29CQ28743129-F6E6F514-5A44-4A81-90B3-C1997DE3C954Q29619512-E3213299-DC8F-44C1-BA5B-4D73E1A88CBCQ33262382-1D52123D-F28A-4905-8BA5-32547AE3F0E1Q33328140-F44FDB3C-3636-4C82-8819-EAD4252D6675Q33782134-A5284106-7084-412B-A1EB-54D518A56394Q33803590-9C201A03-FE9B-47D8-925C-02306A0638E4Q33809112-E6D15597-7F6E-4FF7-B483-091B4EF94C61Q34034659-1FAEEC46-DEBB-47E4-9B68-F7BF723D49D4Q34071790-EFB865CD-FA9F-48C4-85AC-C8754994A1BCQ34145199-8BA793AC-1D5E-4BBE-B80B-8038D6355EBFQ34273397-E42D3020-CB95-48AD-AF6E-BE55E7E8DD3EQ34292765-44552883-2EBD-486C-B011-5241DB1A3D09Q34317025-68DEE31A-7955-406A-856E-4CA68C02F43FQ34406977-29B93EEE-7C70-4106-93AA-6D2690EAE24CQ34543052-EDC32B77-8CC8-445B-B588-4B7DA2FB6389Q34648342-30893A2B-D821-44B3-B890-7C8C2617CEFBQ34867076-3F544891-C3B8-42CD-BF30-B945DF5E0FE1Q35111062-7AF2584B-1B7A-4174-89B0-F102EC16FF95Q35137168-571D0531-DCA9-469D-9F4E-12C026AB7E7CQ35170702-6DAF4E6E-2F52-445F-8FC5-C18754C7F79BQ35600028-57C199B8-7B94-4BA2-8562-D73694CECC39Q35641144-C173FE89-DD90-46CC-B36F-F5A23B5564C8Q35658414-526E8E2C-3BDC-4A47-85E9-DD320ED102F4Q35706462-B649F3B0-ACB8-49F4-8A40-F8E4372A3CC5Q35817106-A4F0BCDE-6CBC-4679-83B0-898413F0E5F3Q35828898-3E5DBADD-CCF3-4D63-8C09-9BCC99B823DDQ35839973-9C084A7A-4F9D-4FAA-BD19-7B0B6AC73A1FQ35848078-24A32706-DAE6-46DF-90A2-5DBC2A73F645Q35848446-FD41536E-6DCD-4982-8F47-791E6F037BEDQ35869892-DA6055CB-7CA0-46DE-AE6B-575413B74FC7Q35890867-6F733B95-B5CA-4B3C-A73D-C9F179C5FF8EQ35913910-D4A5CE23-ACB0-48AA-B726-2C16B86994EFQ36055538-F945EEF9-3772-434B-8D09-B11313824D8FQ36365085-21E16B40-4381-429C-84B9-D727C35BC236
P2860
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
description
1991 nî lūn-bûn
@nan
1991 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
name
Production of site-selected ne ...... type 1 envelope glycoprotein.
@ast
Production of site-selected ne ...... type 1 envelope glycoprotein.
@en
Production of site-selected ne ...... type 1 envelope glycoprotein.
@nl
type
label
Production of site-selected ne ...... type 1 envelope glycoprotein.
@ast
Production of site-selected ne ...... type 1 envelope glycoprotein.
@en
Production of site-selected ne ...... type 1 envelope glycoprotein.
@nl
prefLabel
Production of site-selected ne ...... type 1 envelope glycoprotein.
@ast
Production of site-selected ne ...... type 1 envelope glycoprotein.
@en
Production of site-selected ne ...... type 1 envelope glycoprotein.
@nl
P2093
P2860
P356
P1476
Production of site-selected ne ...... type 1 envelope glycoprotein.
@en
P2093
C V Hanson
C Williams
H W Sheppard
S Karwowska
S Zolla-Pazner
V Gianakakos
P2860
P304
P356
10.1073/PNAS.88.8.3238
P407
P577
1991-04-01T00:00:00Z